Versartis, Inc. (VSAR)

[naturalborninvestor]

In October? Phase 3 drug didn't meet primary endpoint. But the drug still worked pretty well, has some very competitive advantage and the study was designed in a way that couldn't really be surpassed (comparing bi-monthly intake vs. daily intake from competition in hormone therapy application). In short, speculation is that VSAR is still a valuable reverse merger / acquisition candidate. A series of events seems to back that theory. and they are sitting on $3 cash per share.